Eyeworld

*Ex-vivo porcine corneal penetration study. Clinical relevance is unknown. † In pooled clinical studies. | 1. VEVYE® (cyclosporine ophthalmic solution) 0.1% [package insert], Harrow IP, LLC; 2024. 2. Restasis® (cyclosporine ophthalmic emulsion) 0.05% [package insert]. Allergan, LLC; 2024. 3. Cequa® (cyclosporine ophthalmic solution) 0.09% [package insert]. Sun Ophthalmics, LLC; 2024. 4. Sheppard et al., Water-free 0.1% Cyclosporine A Solution for Treatment of Dry Eye Disease: Results of the Randomized Phase 2B/3 ESSENCE Study. Cornea 2021;00:1–8. 5. Akpek et al., Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease The ESSENCE-2 Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2023.0709. April 6, 2023. 6. Data on file. VEVYE and the VEVYE logo are registered trademarks of Novaliq GmbH. Harrow IP, LLC owns the HARROW registered trademark and the HARROW logo trademark. All other trademarks are property of their respective owners. ©2024 Harrow. All Rights Reserved. VYE-00164-h 06/24 T A K E T H E FAST TR ACK T O R E L I E F VEVYE ® is the first and only water-free cyclosporine dissolved in a semifluorinated alkane (SFA) for the treatment of the signs and symptoms of dry eye disease. 1-3 I N D I CAT I O N A N D U S AG E VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease. I M P O R TA N T S A F E T Y I N F O R M AT I O N Warnings and Precautions • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces. • Use with Contact Lenses – VEVYE® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE®. Adverse Reactions • In clinical trials with 738 subjects receiving at least 1 dose of VEVYE®, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%). • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. For additional information about VEVYE®, please see Brief Summary on adjacent page and Full Prescribing Information at vevye.com. High tolerability 99.8% of patients experienced no or mild instillation site pain. 4,5 Rapid onset Demonstrated clinically and statistically significant total corneal fluorescein staining improvement by Day 15 in clinical studies. 4,5

• Blank Page
• Blank Page (1)